Maximum Residue Limits (MRLs)
Guidance for the veterinary pharmaceutical industry on applying for maximum residue limits (MRLs) in the UK.
Who this applies to
This guidance applies to businesses and organisations involved in veterinary medicines and food-producing animals, particularly:
- veterinary pharmaceutical companies and marketing authorisation holders
- businesses applying to establish, extend or change a maximum residue limit (MRL)
- businesses placing veterinary medicines for food-producing animals on the market in Great Britain or Northern Ireland
- other organisations that need to understand the MRL requirements applying to veterinary medicines
UK-EU SPS Agreement Changes
As part of the UK-EU Sanitary and Phytosanitary (SPS) Agreement, Great Britain (GB) will apply EU rules on maximum residue limits (MRLs) for veterinary medicines. This will mean that MRLs in GB will mirror those established in the EU. Northern Ireland (NI) already follows EU rules on veterinary medicines MRLs and will continue to do so.
The changes will help maintain protections for public health, animal health and food safety while making trade between GB and the EU easier. These benefits will be extended for movements from GB to NI through the Agreement’s interplay with the Windsor Framework. The date of application of the SPS Agreement is 1 March 2028. This is the date from which the new requirements will apply. The VMD will continue to publish guidance and provide stakeholder engagement opportunities between now and the application date.
Businesses should continue to follow GB MRLs until the changes take effect and monitor GOV.UK for further updates. For more information about changes in the veterinary sector, see Veterinary Sector: preparing your business.
For general information about the SPS Agreement, see SPS agreement: preparing your business.
The wider veterinary medicines authorisation regime is not in scope of the SPS Agreement.
Maximum Residue Limits in GB
MRLs listed in Commission Regulation (EC) 37/2010 or published in the Official Journal prior to 31 December 2020 continue to have effect in GB and are included on the list of GB approved MRLs. Maximum Residue Limits in Great Britain (PDF, 2.19 MB, 55 pages)
If you plan to apply for an MRL in GB before the application date of the SPS agreement, please contact us to discuss your proposed application. To arrange a meeting, please use the VMD’s online contact form and include ‘Request a company meeting’ in the summary line.
Establishing and amending MRLs under the SPS Agreement in GB
From the application date of the SPS Agreement, you will need to apply to the European Medicines Agency (EMA) to establish a new MRL or amend an existing MRL in both NI and GB.
MRLs established or amended in the EU will apply in the UK.
Find out how to submit a MRL application to the EMA.
Maximum Residue Limits in NI
Under the Windsor Framework, NI operates under EU rules. This means that Maximum Residue Limits (MRLs) established by the European Commission and set out in Commission Regulation 37/2010 must be followed in NI.
You must submit the same application and all procedurally related communications that you provide to the EU to us via VMDS or Eudralink within 2 working days.
Contact
For further information, please contact the VMD via our online contact form.